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ABSTRACT  
The severe worldwide shortage of donor organs, and severe pathologies placing patients at 
high risk for rejecting conventional cornea transplantation, have left many corneal blind 
patients untreated. Following successful pre-clinical evaluation in mini-pigs, we tested a 
biomaterials-enabled pro-regeneration strategy to restore corneal integrity in an open-label 
observational study of six patients. Cell-free corneal implants comprising recombinant human 
collagen and phosphorylcholine were grafted by anterior lamellar keratoplasty into corneas of 
unilaterally blind patients diagnosed at high-risk for rejecting donor allografts. They were 
followed-up for a mean of 24 months. Patients with acute disease (ulceration) were relieved 
of pain and discomfort within 1-2 weeks post-operation. Patients with scarred or ulcerated 
corneas from severe infection showed better vision improvement, followed by corneas with 
burns. Corneas with immune or degenerative conditions transplanted for symptom relief only 
showed no vision improvement overall. However, grafting promoted nerve regeneration as 
observed by improved touch sensitivity to normal levels in all patients tested, even for those 
with little/no sensitivity before treatment. Overall, three out of six patients showed significant 
vision improvement. Others were sufficiently stabilized to allow follow-on surgery to restore 
vision. Grafting outcomes in mini-pig corneas were superior to those in human subjects, 
emphasizing that animal models are only predictive for patients with non-severely 
pathological corneas; however, for establishing parameters such as stable corneal regeneration 
and nerve regeneration, our pig model is satisfactory. While further testing is merited, we 
have nevertheless shown that cell-free implants are potentially safe, efficacious options for 
treating high-risk patients. 
Keywords: recombinant human collagen, phosphorylcholine, cornea, pre-clinical, clinical 
evaluation, regeneration 
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INTRODUCTION 
In tissue engineering and regenerative medicine, exciting new biomaterials and technologies 
such as 3D printing have produced very promising results in animal models, showing 
regeneration in a range of organs.1 However, translation of these remarkable accomplishments 
from animal models to patients in clinical practice has been protracted. One problem is the 
failure to obtain stable and functional integration of biomaterials into chronically damaged, 
diseased or aged tissues, unlike the case with mostly young, healthy animal models.1 The 
limited predictive power of pre-clinical animal studies, which typically involve the use of 
rodents and rabbits, has indeed been identified as the primary barrier for safe translation.2 
More recently, pigs have been proposed as ideal pre-clinical models as the anatomy, 
physiology, and biochemistry of many of their organs,3,4 including their corneas,5 is similar to 
that of humans, allowing for greater predictability of performance of new implants in human 
subjects.  
The human cornea is a relatively simple tissue comprising three main layers, an outer 
multilayered epithelium, a middle stroma consisting of a largely collagenous extracellular 
matrix and cells arranged in layers, and an inner single-layered endothelium. It is highly 
innervated but avascular, and is optically transparent to allow entry of light into the eye for 
vision. Irreversible loss of transparency can result in corneal blindness. Corneal blindness is 
estimated to affect 23 million individuals worldwide6 and is treated by corneal transplantation 
to restore transparency. However, there is a severe worldwide shortage of donor tissues, as 
with other transplantable organs. With only one donor cornea available for every 70 needed,7 
it is evident that an alternative solution to just increasing the donation rate is crucial. 
Furthermore, corneas with inflammation and severe pathologies have a high risk (up to 49%) 
for rejecting conventional donor allografts.6 Over 90% of all cornea blind individuals and in 
particular, high-risk individuals, live in low to middle-income countries (LMICs).6,8 Due to a 
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lack of resources in these countries, the treatment of these high-risk patients with stem cell 
technology is not possible, and the limited supply of donor tissues is prioritized for lower risk 
patients that have a higher chance of successful recovery.9,10 Artificial corneas known as 
keratoprostheses have been developed but only two have been successful in clinical use.11 
However, because of the risk of severe side effects such as potentially blinding glaucoma, and 
the need for immune suppression and lifelong antibiotics, these are generally used only in 
end-stage diseased corneas.12 Full thickness corneal grafting by penetrating keratoplasty (PK) 
remains the mainstay of corneal transplantation globally, particularly in LMICs13 even though 
partial thickness grafts that address only the affected layers are gaining in popularity. For 
damage affecting the epithelium and stroma, partial thickness anterior lamellar keratplasty 
(ALK) is performed. Given the magnitude of the problem with an estimated 1.52 million new 
cases of corneal blindness per year,6 cost-effective, cell-free biomaterials implants that 
promote endogenous regeneration while minimizing the regulatory and scientific challenges 
of specialized cleanrooms14 and immune rejection, are attractive clinical options. 
Our team has previously shown that cell-free implants comprising carbodiimide-
crosslinked recombinant human collagen type III (RHCIII) stimulated stable regeneration in 
conventional cornea grafted patients.15,16 However, for use in high-risk patients, we 
incorporated a second network of 2-methacryloyloxyethyl phosphorylcholine (MPC) as a 
structural element within the implant. MPC is a synthetic lipid reported to suppress 
inflammatory responses,17 and to minimize neovascularization in rabbit models of corneal 
alkali neovascularization.18 In three pilot patients, the use of small tectonic patches of 
RHCIII-MPC to replace excised ulcerated tissue resulted in the successful restoration of 
corneal integrity without any adverse effects.19 
Here, using the transplantation of RHCIII-MPC implants as a test bed, we assessed the 
efficacy of the pig model at predicting clinical outcomes. We examined the results of a pre-
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clinical mini-pig study alongside those of a clinical study involving seven high-risk patients 
with different pre-operative diagnoses. A pre-clinical study of biosynthetic corneas 
comprising RHCIII-MPC was performed in Göttingen mini-pigs to confirm previous safety 
results20 and to examine in detail the micro-architecture and optical properties of regenerated 
neo-corneas. For our clinical study, all  recruited patients had been diagnosed with severe 
corneal pathologies resulting from ocular trauma or infective ocular ulceration and had 
consequently not been prioritized for grafting due to their high risk of donor rejection.21 The 
primary endpoint of the clinical study was safety, i.e. no serious adverse reactions such as 
excessive redness, pain or discomfort, swelling of adjacent corneal tissues or clouding of 
anterior chamber fluid. The secondary endpoints were the restoration of corneal integrity and 
regeneration of neo-corneas by mobilization of endogenous stem cells. The potential benefit 
to patients was the reduction of pain and discomfort to those with active ulcers, and the 
possibility of regaining eyesight in severely scarred eyes. The worst-case scenario was no 
change in vision or the need for re-grafting with a human donor cornea.  
 
RESULTS 
 
RHCIII-MPC implants  
RHCIII-MPC implants comprising 8% RHCIII, 4% MPC and 1.3% PEGDA were 
fabricated following Medical Devices Directive MDD 93/42/ECC and associated ISO 
standards in a certified and monitored cleanroom at Vecura AB, Karolinska University 
Hospital, Huddinge, Sweden. Only implants meeting quality control criteria such as 
comparable optical quality to the human cornea were used (Table 1A). Implants exhibited 
92% light transmission,22 which is above the minimum of 87% for healthy human corneas.23 
The refractive index of the implants was 1.334, similar to water (1.333) and marginally lower 
than that of the human cornea at 1.373.24,25 Denaturation temperature was 51°C, lower than 
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that of the human cornea at 65°C26 but well above the highest body temperature ever recorded 
at 45°C.27 
 
Implants in mini-pigs 
RHCIII-MPC hydrogels, 6.75 mm in diameter, 500 µm thick were implanted the corneas of 
Göttingen mini-pigs by ALK, replacing the epithelium and anterior stroma, leaving the 
endothelium and posterior stroma intact. Implanted corneas were optically transparent like 
healthy, untreated control corneas at 12 months post-operation (Fig. 1A). In vivo confocal 
microscopical examination of the neo-corneas showed regenerated epithelium, stroma, and 
nerves (Supplementary Fig. 1), confirming the safety and efficacy reported in previous animal 
studies.20,22 Ultrastructural imaging using serial block face scanning electron microscopy 
(SBF-SEM) showed that both implanted corneas and unoperated controls had very similar 
epithelia and stromas. The epithelia in both had a well-defined layer of basal cells and layers 
of flattened interconnecting cells (keratocytes) were evident within the stroma (Fig. 1A).  
As assessment of visual acuity or best-corrected visual acuity (BCVA) in mini-pigs 
was not possible, we examined the optical similarity of regenerated neo-corneas to that of 
healthy controls. Under white light illumination, the measured light transmission and 
backscatter values of the regenerated neo-corneas at 12 months post-operation did not differ 
significantly from that of the healthy, unoperated corneas (Fig. 1 B and C; P> 0.05). 
Furthermore, when examined over a range of visible light wavelengths (450-650 nm), no 
significant differences in light transmission were detected between the operated and un-
operated corneas (P>0.05). However, the gradual drop in light transmission with decreasing 
wavelength, which was seen in both the operated and un-operated corneas, appeared to be 
slightly more pronounced in the regenerated neo-corneas (Fig. 1B). Values for percentage 
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backscatter of light in the operated and unoperated corneas were almost identical over the 
entire visible light spectrum (Fig. 1C). 
 
Implants in patients 
An open-label, first-in-human observational study was conducted following ISO 14971 - 
Medical devices – Application of risk management to medical devices, and ISO 14155 - 
Clinical investigation of medical devices for human subjects – Good clinical 
practice.  Clinical testing in Ukraine was performed in following the Declaration of Helsinki 
and relevant laws of Ukraine, following trial approval (ClinicalTrials.gov identifier 
NCT02277054) by the Bioethics Commission of the Filatov Institute of Eye Diseases and 
Tissue Therapy of the National Academy of Medical Sciences of Ukraine (FEI). In India, 
clinical testing was performed in accordance with the Declaration of Helsinki, relevant laws 
of India and after approval by the ethics committee (LEC 01-14-014) of the LV Prasad Eye 
Institute (LVPEI) and trial registration at Clinical Trial Registry-India 
(CTRI/2014/10/005114). 
Seven unilaterally blind patients, aged 36 to 76 years old, diagnosed with conditions 
putting them at high risk of rejecting conventional corneal transplantation, and capable of 
providing informed written consent were recruited. Supplementary Table 1 shows the 
inclusion, exclusion criteria. Patients were divided into three groups based on the cause of 
corneal damage: infection, burns (chemical or thermal) and other (immune/degenerative 
disease) (Table 1B). The patients were also divided into two groups based on their stage of 
disease – acute phase (with ulcers and erosions) and post-scarring (severe scarring in need of 
scar revision). Before implantation, all acute patients suffered from chronic, recurrent 
episodes of pain accompanied by redness, photophobia, and tearing related to corneal de-
epithelialization (Table 2B). Patients with severe scarring were asymptomatic. 
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All implants were well-tolerated over a follow-up period of 24± 6.6 months (range of 
14-35 months) without immunosuppressive steroids beyond four weeks of prophylaxis, 
compared to up to 12 months of steroids for conventional PK allografts and even longer for 
high-risk grafts.  
Clinical outcomes at the last follow-up varied depending on initial diagnosis (Table 
2A). Patients with ulcers or scarring due to infection (Patients 1-3) showed the most 
improvement, followed by those with burns (Patients 4-5). The two patients with immune and 
degenerative disorders, i.e. previously rejected graft (Patient 6) and neurotrophic keratitis 
(Patient 7) performed most poorly. 
Overall, epithelial cell migration over the implants took 4-50 weeks post-operation, 
being significantly slower in patients with diagnosed stem cell deficiency, but the healed 
ocular surface remained stable in all patients (Table 2A). 
In Patients 1-3, who had an ulcer or severe scarring due to infections, the implants 
were well-tolerated and stably incorporated. They remained relatively clear and edema-free 
(Fig. 2). Patient 1’s vision improved from near blindness (light perception) to 1.3 LogMAR at 
two weeks post-operation, to 0.7 LogMAR at three months and 0.52 LogMAR at eight 
months post-operation (moderate vision loss). Her vision remained stable over the 24 months 
follow-up period (Table 2A). In vivo confocal microscopical examination showed that she had 
fully regenerated epithelium and stroma, and her endothelium remains healthy (Fig. 3). A few 
corneal nerves were visible (Fig 3). At one-week post-operation, Patient 2’s vision had 
improved from 1.6 to 1.1 LogMAR. Complete epithelial coverage of the implant occurred 
over 12 weeks (Table 2A). The implant remained clear, free of edema and neovascularization. 
BCVA improved to 0.1 LogMAR (normal vision) by six months post-operation and remained 
stable over a follow-up period of 35 months. Ultrasound biomicroscopy and optical coherence 
tomography confirmed the preservation of the cornea curvature in Patients 1 and 2 that was 
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restored by implantation (Supplementary Fig. 2). The vision of Patient 3 improved from 1.6 to 
1.0 LogMAR at one-month post-operation (Table 2A). Unfortunately, he developed fungal 
keratitis at six weeks post-operation. Although this was deemed unrelated, as pathology 
findings showed the implant was untouched by fungus, the patient required therapeutic 
penetrating keratoplasty and was excluded from the study. All three patients had normal 
intraocular pressure (IOP).  
In Patient 4, who had an alkali burn, healing was accompanied by implant thinning 
due to delayed epithelialization. Vision improved slightly from light perception to 2.0 
LogMAR at 2 months and 1.7 LogMAR at last follow-up at 24 months, but the patient was 
still considered blind (Table 2A). Patient 5, who had a thermal burn pre-operatively, showed 
improved vision from near blindness (light perception) to 1.4 LogMAR at nine months post-
operation and slightly decreased to 1.52 LogMAR (severe vision loss) at last follow-up at 14 
months. It should be noted, however, that this patient also had a senile cataract that had 
progressed during the follow-up period, impeding vision despite an almost clear cornea. IOP 
was normal in both patients 4 and 5. Superficial vessels were seen in these corneas, which 
were previously vascularized and with limbal epithelial stem cell deficiencies (Fig. 2). These 
vessels were associated with invading adjacent conjunctiva. However, ultrasound 
biomicroscopy confirmed the preservation of the cornea curvature restored by implantation in 
both patients (Supplementary Fig. 2). 
Patient 6 was blind due to glaucoma and had no light perception. He was grafted for 
symptom relief due to ulceration of a rejected corneal graft. Although the implant remained 
relatively clear, it was encircled by blood vessels, and these had invaded the implant margin 
at the six to seven o’clock position. In Patient 7, the implant site was thickened considerably 
by epithelial hyperplasia causing the graft to become opaque, but the regenerated corneal 
tissue remained stable. The vision of Patient 7 was 1.4 LogMAR at one-month post-operation, 
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and despite cornea thickening remained stable throughout the follow-up and reached 1.3 
LogMAR at last follow-up at 24 months post-operation. IOP was within the normal range for 
Patient 7 but not Patient 6 who had glaucoma before surgery (Table 2A). 
Most notably, however, all five patients with acute disease and suffering from pain, 
irritation, and photophobia due to the ulceration, became asymptomatic within 1-2 weeks 
post-operation and remained as such at the last follow-up (Table 2B).  
Before surgery, all acute phase patients had reduced touch sensitivity from slight to the 
total absence of response (Figure 3B). After surgery, sensitivity in all patients was restored to 
levels observed in their healthy contralateral corneas, including the individual with 
degenerative neurotrophic keratitis (Patient 5). Kruskal-Wallis test showed a significant 
difference between average pre-operative sensitivity compared to contralateral eyes (p<0.05).  
 
DISCUSSION 
RHCIII-MPC implants have been evaluated in a range of animal models including mice,28 
rabbits18 and mini-pigs.20 The mouse implantation model is a rejection model and only 
provides information on implant performance relative to allografting.28 Rabbits have been 
used extensively in the pre-clinical testing of new corneal implants. For example, in a well-
established alkali burn model that simulates severe pathology,29 we were able to show that the 
addition of the inflammation suppressing MPC to RHCIII biosynthetic corneas resulted in the 
implants remaining stably incorporated and clear.18 In contrast, burned corneas grafted with 
RHCIII only, like allografts, were vascularized.18  However, rabbit corneas differ from human 
corneas in that they are thinner, have no Bowman’s membrane and their endothelial cells 
proliferate readily.30,31 The pig cornea is structurally and mechanically closer to the human 
cornea,5,32 in that it possesses a Bowman’s membrane and an endothelium with minimal 
proliferative capacity. 
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In the present study, ultrastructural examination of the regenerated neo-cornea after 
RHCIII-MPC implantation in mini-pigs showed a micro-architecture that resembled that of 
healthy, unoperated corneas. The implants had stimulated the pig’s endogenous corneal 
progenitor cells to migrate into the implant, proliferate and recreate a neo-cornea. Optically, 
the regenerated neo-corneas also matched the healthy, unoperated corneas in allowing light 
transmission through the tissue with minimal back scatter.  
As in the pre-clinical mini-pig study, the implants successfully stimulated endogenous 
cells to affect corneal repair in all of the six patients that completed the study. In most 
patients, the restored corneal surface led to improvements in BCVA that were maintained 
throughout the entire follow-up period of 14 to 35 months. The exception to this was Patient 6 
who was blind due to glaucoma and therefore not expected to regain vision. All of the other 
patients showed vision improvement, but only two showed significant improvement from 
legally blind to vision impaired, and one gained normal vision. The vision of one of these 
patients was hampered by an unrelated senile cataract in his lens. Stem cell deficiency and 
conjunctival invasion were the main barriers to vision improvement. As the implants restored 
corneal stromal integrity, shown by the relief from pain, discomfort and photophobia, patients 
with stem cell deficiency can potentially undergo subsequent treatment to restore vision, e.g. 
if sufficient funding can be raised. Nevertheless, the healing and in-growth of cells to form 
neo-corneal tissue occurred and remained stable over the entire follow-up period, as seen in 
pre-clinical mini-pig model.  
Epithelial coverage of RHCIII-MPC implants was significantly slower than reported 
for patients grafted with donor corneas by ALK or human amniotic membranes (HAM) to 
treat corneal thinning.33 The delayed epithelial closure is most likely due to retention 
techniques used15 as overlying sutures or excess glue retarded epithelial coverage creating an 
epithelial defect-like situation that most likely initiated an early inflammatory response. This 
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was likely followed by induction of metalloproteinases and subsequent localized implant 
thinning. Corneal thickening due to epithelial hyperplasia, such as seen in one patient has 
been previously observed to a lesser extent in patients after refractive surgery34 and laboratory 
animals after corneal transplantation.35 Nevertheless, we have shown for the first time that 
RHCIII-MPC implants can be glued (albeit with caution with amounts used), opening up 
possibilities for future use as patches that may circumvent the need for transplantation. 
A recent study comparing treatments for corneal ulceration showed that 100% of 
patients grafted with donor corneas by ALK became neovascularised.33 HAM grafts 
suppressed neovascularization but the membranes disintegrated within 6 months.33 Here, 
neovascularization was observed in the pre-operatively neovascularised corneas with limbal 
epithelial stem cell deficiencies. Neovascularisation concurrent with conjunctival invasion is 
common in corneas with limbal stem cell deficiency.36 These patients had severely damaged 
or scarred corneas so it is not surprising that their post-operative results and those of three 
earlier pilot patients19 were not as good as the outcomes seen here and elsewhere in healthy 
mini-pig corneas20 or even rabbit corneas after alkali injury.18 This discrepancy between 
animal data and clinical outcomes is typical when translating promising animal results into 
clinical application. Present results also show that recovery from a severe pathology has a 
different course to that seen in low risk patients.15,11 In low-risk patients, vision restoration 
was the indication for grafting but in high-risk patients, corneal surface restoration and 
symptom relief were the main indications for treatment of acute patients although vision 
improvement was the goal for scarred patients.  
 Very few therapeutic interventions promoting nerve regrowth into the cornea exist.37 
In donor corneas grafted by ALK or PK, touch sensitivity remains low post-operatively.37 In 
our pre-clinical pig models, nerve regeneration was a main feature. We also noted 
regeneration of the different corneal nerve sub-types in guinea pigs grafted with collagen-
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MPC implants.38 Aesthesiometry performed on the acute phase patients showed that touch 
sensitivity, which is correlated with nerve function,39 was restored to normal levels in all five 
patients. Surprisingly, the functional restoration was also observed in Patient 7 who had no 
pre-operative touch sensitivity due to neurotrophic keratitis, a degenerative condition. HAM 
treatment has been reported to increase sensitivity in 9 out of 10 patients with similar profiles 
to our five patients.40 However, these patients had higher pre-operative sensitivity than our 
patients and their final sensitivity was just below normal. HAM contains a high concentration 
of growth factors and likely trophic factors that suppress inflammation,40 while the MPC used 
in our implants has reported anti-inflammation effects.17 Taken together, both observations 
strongly suggest that suppression of persistent inflammation in chronically ulcerated corneas 
facilitated nerve regeneration.  
Following corneal wounding, elaboration of disorganized, unaligned mainly type III 
collagen occurs to form a scar.41 Here, bridging the wound gape with an organized matrix 
comprising aligned type III collagen,22 however, appears to provide a template for controlled 
in-growth of stromal cells that in turn allows for regeneration of an optically clear cornea. 
Furthermore, complications such as graft rejection (45% in high-risk patients) are likely 
elicited by the vascularized or inflamed host cornea reacting against the presence of 
allogeneic cells,42 were circumvented by use of cell-free implants. The inflammation 
inhibiting MPC networked within the implants most likely contributed to the capacity of 
RHCIII-MPC implants to remain quiescent in the immunogenic corneas, allowing stable 
restoration of the ocular surface.  
It would also be pertinent to mention that even though stem cell replacement is an 
option in more affluent settings, there is still an issue with allogeneic transplantation that has 
not been solved. Systemic immune suppression is required for allografted corneal limbal 
epithelial cells, with reported severe side-effects that include anemia, hyperglycemia, elevated 
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creatinine, and elevated levels of liver function markers.43 Furthermore, if the damage extends 
into the stroma, as seen in our patients, a second surgery requiring a human donor cornea is 
still needed.43 Here, the cell-free implants stimulated endogenous stem cells to affect the 
repair in both stroma and epithelium, together with nerve regeneration without immune 
suppression beyond prophylaxis. 
With clinical application as the goal, synthetically-produced recombinant human 
collagen was used to circumvent immunogenic reactions that can occur with animal-derived 
collagen in susceptible patients due to their non-human protein composition,44 and pathogen 
transmission risks. Furthermore, our collagen-based biomaterials made for the cornea have 
been modified for use in other systems,45-47 as similar conditions such as skin ulcers in legs of 
diabetics, are enormous problems in LMICs.48 
While confirmation in a larger number of patients is needed, we nevertheless 
demonstrate that implantation with cell-free RHCIII-MPC implants is a safe, reliable option 
for treating patients at high risk of donor allograft rejection; providing pain relief, and 
regenerating tissue and nerves. The clinical outcomes in humans although not as ideal as 
those in pre-clinical studies, nevertheless were predictable by use of wild-type mini-pigs as a 
model. 
 
METHODS 
 
RHCIII-MPC corneal implants 
European Medical Devices Directive MDD 93/42/ECC and its associated ISO standards were 
followed. For clinical evaluation, implants were made within an EU Class A laminar flow 
hood located in a Class B certified and monitored cleanroom 
at Vecura AB, Karolinska University Hospital, Huddinge, Sweden. Aseptic working 
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conditions and sterile chemicals and reagents were used in the cleanrooms for implant 
production. Water for injection (WFI, HyClone, Utah, USA) was used to make up all 
solutions.  For pre-clinical animal testing, implants were made under aseptic conditions in 
certified tissue culture hoods approximating Class A conditions. 
Very briefly, implants were fabricated by mixing an 18% (wt/wt) aqueous solution 
RHCIII (FibroGen Inc., San Francisco, CA) with 2-
methacryloyloxyethyl phosphorylcholine (MPC, Paramount Fine Chemicals Co. Ltd., Dalian, 
China) and poly(ethylene glycol) diacrylate (PEGDA, Mn 575, Sigma-Aldrich) in 
a morpholinoethane sulfonic acid monohydrate (MES, Sigma-Aldrich, MO) buffer. The ratio 
of RHCIII:MPC was 2:1 (wt/wt) and PEGDA:MPC was 1:3 (wt/wt). Polymerization initiators 
ammonium persulphate (APS; Sigma-Aldrich) and N,N,N,N-
tetramethylethylenediamine (TEMED, Sigma-Aldrich) at ratios of APS:MPC = 0.03:1 
(wt/wt), APS:TEMED (wt/wt) = 1:0.77, crosslinker, N-(3-dimethylaminopropyl)-N'-
ethylcarbodiimide (EDC; Sigma-Aldrich) and its co-reactant, N-hydroxysuccinimide (NHS; 
Sigma-Aldrich) was then mixed in. The resulting solution was dispensed into cornea-shaped 
moulds and cured. After demoulding, they were washed thoroughly with phosphate buffered 
saline (PBS) and placed into vials of aseptic PBS containing 1% chloroform, which 
were sealed to maintain sterility.   
During quality control, each implant was visually inspected for manufacturing 
flaws, discolouration or unwanted particulates under a dissection 
microscope. Those with imperfections were rejected. Batch controls were also performed on 
randomly selected implants, one from each batch (1 out of every 4 samples). Implants tested 
were found sterile, with endotoxin levels below the requirement of <0.5EU/ml cut-off 
requirement for implantable medical devices49,50 by a Swedish Medical Products Agency 
approved laboratory (Apotek Produktion & Laboratorier AB, Stockholm, Sweden). Implants 
were tested to ensure their flexibility. Refractive index measurements were made using an 
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Abbe 60 series Refractometer (Bellingham & Stanley Ltd., Kent, UK) calibrated against a 
silica test plate of known refractive index at room temperature. Light transmission through 
implants was measured by a UV-VIS spectrophotometer (U-2800 UV-VIS, Hitachi, Tokyo, 
Japan).  Implant materials (5x15mm) were placed in the spectrophotometer with a quartz 
cuvette within the spectrophotometer in such a way that the beam was perpendicular to the 
hydrogel. Light absorption by the hydrogel was measured in the visual spectrum (400 nm to 
700 nm). The equilibrium water content of hydrogels was determined to ensure 
uniformity.  Hydrated hydrogels were removed from solution; the surface gently blotted dry 
and then immediately weighed on a microbalance to record the wet weight (W0) of the 
sample. The hydration of the hydrogels shown in Table S1 was calculated using a dry weight 
obtained by drying the samples at 60 degrees until constant mass was achieved (W). The 
equilibrated water content of the hydrogels (Wt) was calculated according to the following 
equation: Wt = (W0–W) / W0 x 100%  
The thermal stability of the implants was examined by measuring the denaturation 
temperature using a differential scanning calorimeter (DSC, Q20, TA Instruments, New 
Castle, UK). Heating scans were recorded in the range of 10 to 80°C at a scan rate of 1°C 
min−1. The samples ranging in mass from 3 to 5 mg were surface dried and hermetically sealed 
in pans. The denaturation temperature (Td) at the maximum of the endothermic peak was 
measured. Implants needed to pass both the visual inspection and batch sampling to be 
acceptable for clinical evaluation. 
 
Pre-clinical evaluation in mini-pigs 
The study was carried out by Adlego Biomedical AB (Solna, Sweden), an approved GLP 
certified pre-clinical testing CRO. The methods were performed were approved by the 
regional ethics committee (Stockholm norra djurförsöksetiska nämnd) and in compliance with 
the Swedish Animal Welfare Ordinance and the Animal Welfare Act and OECD Principle of 
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Good Laboratory Practice, ENV/MC/CHEM (98) 17, 1997. Corneal implantation was 
performed in four female Göttingen SPF mini-pigs (Ellegaard, Denmark), 5-6 months old. 
Two weeks before surgery the animals were given a thorough clinical examination to 
establish a baseline for corneal health. During the surgery, the right cornea of each pig was 
trephined with a 6.5 mm diameter Barron Hessberg trephine to a depth of 500 μm. The 
corneal button was dissected lamellarly with a diamond knife and removed. A RHCIII-MPC 
implant, trephined to 6.75 mm in diameter was put into the wound bed. Human amniotic 
membrane (HAM; from the Cornea Bank, St. Erik’s Eye Hospital, Stockholm, Sweden) was 
placed over the implant to suppress undesired inflammation and the implants were held in 
place with overlying sutures. An antibacterial and anti-inflammatory ophthalmic solution 
(Tobrasone®, suspension with 3 mg/mL dexamethasone and 1 mg/mL tobramycine, Alcon, 
Sweden) was administered post-operatively. Each pig also received buprenorphine i.v. (0.05 
mg/kg Vetergesic®, Orion Pharma, Finland). Subsequently, the operated eyes were treated 3 
times daily with 1 drop Tobrasone®. Unoperated contralateral corneas served as controls.  
 Another four mini-pig implantations in Canada were approved by the University of 
Ottawa animal ethics committee (Protocol E-19) in compliance with the animal care 
guidelines of the Association for Research in Vision and Ophthalmology, using similar 
methods. These corneas were used for measurement of optical properties. 
At 12 months post-operation, after clinical data acquisition, the animals were 
euthanized and both implanted and control corneas were harvested. Histopathological 
evaluation of GLP animals were performed by a Swedish MPA approved veterinary 
pathologist, BioVet AB (Sollentuna, Sweden). Optical properties such as % light transmission 
through the regenerated neo-corneas and the control unoperated eyes, and amount of back 
scattered light (%) were determined by measuring freshly excised corneas on a custom-built 
instrument equipped with a quartz halogen lamp for white light measurements as we 
previously reported.51 
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The mini pig corneal control and RHCIII-MPC implanted samples were fixed using 
2.5% glutaraldehyde/2% paraformaldehyde in 100mM cacodylate buffer pH 7.2 at room 
temperature for 12 hours. The samples were then processed for the generation of high 
backscatter electron contrast for serial block face scanning (SBF SEM) as previously 
described.52 The samples were then transferred to a Zeiss Sigma VP FEG SEM equipped with 
a Gatan 3View2XP system, where data sets of 1000 images were acquired of the block 
surface every 100 nm through automated sectioning. Each image on the SBF-SEM was 
acquired at 4K X 4K pixels, at a pixel resolution 32nm and a pixel dwell time of 8 µs, using 
an accelerating voltage of 3.4keV in low vacuum variable pressure mode (28 Pa).  Imaging 
data was acquired from a 134.93 µm X 134.94 µm region of interest. Selected serial image 
sequences were extracted from the image data and 3D reconstructions were generated using 
Amira 6.1 software (FEI Merignac, France) 
 
Patient Surgeries and Follow-up 
At FEI, after providing written informed consent, patients were each grafted with a 350 µm 
thick RHCIII-MPC implant by ALK after manual excision of 300 μm of pathologic 
epithelium and stroma, except for Patient 2 who had a swollen, calcified cornea, and required 
excision of 900 µm of pathologic tissue. The excised pathological tissues, where available, 
were processed for histopathological examination. In two patients, only detritus was present 
so histopathology was not possible. The implants were retained by overlying sutures placed 
peripherally.15 After surgery, grafted patients received antibiotic eye drops 
(ofloxacin  ophthalmic solution, 0.3%, Bausch & Lomb GmbH, Dr. Gerhard Mann chem.-
pharm. Fabrik GmbH, Berlin, Germany) 4 times daily, short-
term mydriatic (cyclopentolate 1%, Sentiss Pharma Pvt. Ltd., Gurgaon, India) and non-
steroidal anti-inflammatory drug (Indometacin 0.1%, Bausch & Lomb GmbH) for 2 weeks, 
followed by topical antiseptic (chlorhexidine bigluconate 0.02%, Farmacia, Lugansk, 
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Ukraine) and steroid (dexamethasone 0.1%, s.a. Alcon-Couvreur n.v., Puurs, Belgium) 3 
times per day for the first week and tapered over 3 weeks to reduce post-operative 
inflammation. Patients wore bandage contact lenses until epithelial regeneration was 
complete. Sutures were removed between 3 and 12 weeks post-operatively in all patients 
except Patient 5, where the epithelium had grown over the sutures.  
After providing written informed consent, LVPEI patients were each grafted with an 8 
mm diameter, 350 µm thick implant by ALK after femtosecond laser (VisuMax, Carl 
Zeiss Meditec, Jena, Germany) assisted excision of 350 μm of pathologic epithelium 
and stroma. The implant was prepared using femtosecond laser and was retained using fibrin 
glue aided by overlying sutures placed peripherally.15 After surgery, patients were 
given moxifloxacin HCl ophthalmic solution 0.5% (Alcon, Fort Worth, USA) 4 times per day 
until re-epithelialization and topical 1 % Prednisolone acetate ophthalmic solution, (Allergan, 
Irvine, USA) 4 times per day for the first week and tapered over 3 weeks to reduce 
postoperative inflammation. Patients wore bandage contact lenses until re-epithelialization. 
Sutures were removed at 3 weeks post-operation.  
All patients were assessed weekly until one month and then at 3 and 6 months, and 
then at 3-4 monthly intervals thereafter. Assessments of best-corrected visual acuity (BCVA), 
intraocular pressure (IOP), tear production (Schirmer test), were made and slit-lamp 
microscopy was performed with and without fluorescein to confirm epithelial integrity. 
Patients also underwent ultrasound biomicroscopy (Aviso, Quantel Medical, Cournon-
d'Auvergne, France) and in vivo confocal microscopy (ConfoScan4, Nidek, Japan) at FEI.  At 
LVPEI, patients were examined by anterior segment optical coherence tomography 
(RTVue, Optovue Inc, Fremont, USA) to assess the cornea and anterior chamber. Nerve 
regeneration as evaluated by regaining of corneal touch sensitivity, was assessed using 
a Cochet-Bonet aesthesiometer (Luneau Oftalmologie, France). Very briefly, the 
aesthesiometer uses a 0.12 mm diameter nylon filament to obtain a blink response.39 
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Statistical Analyses  
Quality control data in Table 1 are expressed as means ± SD. For optical properties measured 
for pig corneas, pairwise t-tests for white light and each wavelength was performed, with a 
Bonnferroni correction. Measurements of corneal nerve sensitivity were statistically evaluated 
using a Kruskal-Wallis test with Dunn’s correction for multiple comparisons. P values of 
<0.05 were considered significant. 
 
Data Availability Statement 
Data analysed during the current study are included in this article and its supplementary 
information files. Clinical trial protocols are available through Clinicaltrials.gov (ID: 
NCT02277054) and the WHO International Clinical Trials Registry Platform 
(http://apps.who.int/trialsearch/; ID: CTRI/2014/10/005114).  The individual patient data that 
support the findings are not publicly available due to patient confidentiality. Datasets 
generated are available from the corresponding authors (MG, VS, KMM) on reasonable 
request. 
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FIGURE LEGENDS 
 
 
Fig. 1. Regenerated corneas of Göttingen mini-pigs at 12-months post-grafting with RHCIII-
MPC compared to healthy, unoperated control corneas. A. control cornea versus RHCIII-
MPC implanted cornea both showing comparable optical clarity. Serial block face-scanning 
electron microscopy (SBF-SEM) of single sections show that the epithelium is multilayered 
with comparable morphology including a layer of basal cells. Underlying the epithelium are 
stromal keratocytes arranged in lamellae. 3D reconstructions of the corneas show that both 
regenerated neo-cornea and healthy control comprise stromas with keratocytes arranged in 
highly ordered lamellae. B. Light transmission profile of regenerated neo-corneas compared 
to healthy contralateral corneas. C. Backscatter profile of regenerated neo-corneas compared 
to healthy contralateral corneas.   
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Fig. 2. Patient corneas before and after grafting with RHCIII-MPC implants at last follow-up. 
Patients are divided into three groups based on their pre-operative diagnoses:  infection 
(herpes simplex and fungal keratitis), burns (alkali and thermal) and other (failed graft and 
post-stroke neurotrophic keratitis). Post-operation, regenerated neocorneas from Patients 1 
and 2 are mostly clear. In Patients 3 and 4, where stem cell deficiency is present, some 
superficial vessels concurrent with conjunctival invasion are seen. Patient 5 has a mostly clear 
cornea encircled by blood vessels but has invaded in one quadrant, while Patient 6’s cornea 
remains hazy. Patient 2 has an unrelated nasal pterygium.  
 
Fig. 3A. In vivo confocal images of the regenerated cornea from Patient 1 at 24 months post-
operation, showing the regenerated epithelium, regenerating nerve (arrowhead) and stroma. 
The unoperated endothelium remains intact. B. Changes in corneal touch sensitivity before 
and after RHCIII-MPC implantation as measured by Cochet-Bonnet aesthesiometry. The 
average pressure required to elicit a blink response from corneas before surgery, after 
implantation, and in comparison to the normal, healthy corneas. Touch sensitivity is inversely 
related to the pressure needed to elicit a blink response from the patients. Note:  *p<0.05 
compared to unoperated contralateral eyes (Kruskal-Wallis test with Dunn’s correction for 
multiple comparisons).  
 
TABLES 
 
 
Table 1. RHCIII-MPC implants and summary of pre-operative patient diagnoses. 
 
A. Characteristics of corneal implants used in the study (n= 3). 
 
Properties 
Transmission in 
white light (%) 
 
Refractive index 
Denaturation 
temperature 
(°C) 
Water content 
(%) 
Implants 92.4±0.122 1.334±0.000322 51.0±1.51 89.37±2.1 
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QC acceptance 
criteria 
 
≥85 1.1-1.5 ≥50 ≥85 
Human cornea 87.1±2.023 1.373-1.38024 65.126 7825 
     
 
 
B. Summary of pre-operative patient diagnoses. Other underlying, pre-existing conditions 
are shown in brackets. 
 
Cause Age Gender 
Stage of 
Disease 
Diagnosis LESCD Vascularised? 
Start of disease 
until treatment (m) 
 
Infection 
Patient 1 64 F acute 
herpes simplex 
keratitis 
no no 5 
Patient 2 36 F scar fungal keratitis no no 8 
Patient 3 56 M scar 
herpes simplex 
keratitis 
no no 72 
Burns 
Patient 4 58 F acute alkali burn yes yes 480 
Patient 5 73 M acute 
thermal burn 
(senile cataract 
in lens that 
impeded vision) 
yes yes 7 
Other 
Patient 6 76 M acute 
rejected graft 
(no light 
perception due 
to glaucoma) 
yes yes 3 
Patient 7 47 M acute 
neurotrophic 
keratitis 
yes no 13 
 
 
 
Table 2. Patient outcomes after RHCIII-MPC implantation. 
 
 
A. Clinical Outcomes after RHCIII-MPC implantation at last follow-up. 
 
Patient 
No. 
Graft 
diam. 
(mm) 
Suture 
removal 
(Weeks 
after 
surgery) 
Full 
epithelial 
coverage 
(Weeks 
after 
surgery) 
BCVA 
pre-op 
LogMAR 
BCVA at 
last 
follow-
up, 
LogMAR 
IOP 
at last 
follow-up 
in the 
operated   
eye 
(mmHg) 
IOP at 
last 
follow-
up 
fellow 
eye 
(mmHg) 
Schirmer 
test at 
last 
follow-
up 
operated 
(mm/ 
5 min) 
Schirmer 
test at 
last 
follow-
up fellow 
(mm/ 
5 min) 
Corneal 
pachymetry 
Pre-op 
(µm) 
Corneal 
pachymetry 
at last 
follow-up 
(µm) 
 
Neovascularization 
of implant area at 
last follow-up 
Follow- 
up 
(months) 
1 6 8 4 LP 0·52 17 15 10 15+ 250 470 no 24 
2 8 3 12 1.6 0.1 14 12 16 20 484 270 no 35 
3* 8 3 - 1.6 1·0 NA NA NA NA 550 NA NA 1.5 
4 7 12 50 LP 1.7 13 14 15+ 15+ 1200 260 yes 24 
5 5 6 7 LP 1·3 19 18 6 10 320 320 yes 14 
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6 4 12 48 NLP NLP 25 15 14 14 410 560** yes 24 
7 4 n/r 4 LP 1.3 16 16 9 8 220 1400 yes 24 
*Patient 3 dropped out of the trial due to an unrelated fungal infection that was treated by 
penetrating keratoplasty. His last follow-up examination was at 1 month post-operation. 
**18 months data 
LP – light perception; NLP – no light perception; n/r - not removed. 
 
 
B. Symptoms before surgery and at last follow-up after RHCIII-MPC implantation.  
No. Photophobia / pain Tearing Redness 
Before After Before After Before After 
1 + - + - + - 
2 - - - - - - 
3 - NA - - - NA 
4 + - + - + - 
5* + - + - + - 
6 + - + - + - 
7 + - + - + - 
 
Notes. ‘+’ - symptom is present, ‘-’ – symptom is not present, ‘NA’ – data not available. 
*Patient 5 did not come in for his 24m follow-up but reported no symptoms when interviewed 
over the telephone by surgeon, OB at 24m. 



